Targets › HTR1B
6 programs from 4 companies in 8 trials: 6 Phase 1, 2 Phase 2; Other, Neurology, Psychiatry; next expected readout Dec 2026.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). (UniProt, P28222)
Open in Phaseline: the race on HTR1B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Basel, Switzerland | Lysergic Acid Diethylamide Tartrate (LSD) Serotonin receptor agonist (5-HT1B/1D/7) | HTR1B, HTR1D | Phase 2 | Palliative Care; Cluster Headache | Sep 2027 |
| Yale University | Dimethyltryptamine (DMT) Serotonin 5-HT receptor agonist; endogenous psychedelic compound | HTR1A, HTR1B, HTR1D, HTR2A | Phase 1 | Major Depressive Disorder; Alcohol Use Disorder (AUD) | Dec 2026 |
| Technophage | Eletriptan Hydrobromide Serotonin 1f (5-HT1f) receptor agonist; Serotonin 1b (5-HT1b) receptor agonist; Serotonin 1d (5-HT1d) receptor agonist | HTR1F, HTR1B, HTR1D | Phase 1 | Acute Spinal Cord Injury (SCI) | Dec 2026 |
| Leukos Biotech | LB-208 HTR1B antagonist | HTR1B | Phase 1 | Solid Tumor Malignancies | Dec 2026 |
| University Hospital, Basel, Switzerland | DMT 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
| University Hospital, Basel, Switzerland | LSD 5-HT receptor agonist, primarily 5-HT1A and 5-HT7 | HTR1A, HTR1B, HTR1D, HTR5A, HTR7 | Phase 1 | Healthy | – |
Healthy (2) Palliative Care (1) Cluster Headache (1) Major Depressive Disorder (1) Alcohol Use Disorder (AUD) (1) Solid Tumor Malignancies (1) Acute Spinal Cord Injury (SCI) (1)
small molecule (6)
University Hospital, Basel, Switzerland (3) Yale University (1) Leukos Biotech (1) Technophage (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.